Last reviewed · How we verify
NCT02003612
Historical Data Analysis of Hematological Remission and Survival in Adults With R/R Acute Lymphoblastic Leukemia
trial testing Not applicable - observational study in Acute Lymphoblastic Leukemia in 2,373 participants. Completed in 28 April 2014.
10 January 2014
Quick facts
| Lead sponsor | Amgen |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 2,373 |
| Start date | 1 October 2013 |
| Primary completion | 10 January 2014 |
| Estimated completion | 28 April 2014 |
| Sites | 10 locations across France, Italy, United Kingdom, Germany, Poland, United States, Spain, Czechia |
Drugs / interventions tested
- Not applicable - observational study
Conditions studied
- Acute Lymphoblastic Leukemia — all drugs for Acute Lymphoblastic Leukemia →
Sponsor
Amgen — full company profile →
Who can join
15 and older, any sex, with Acute Lymphoblastic Leukemia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A retrospective analysis of historical data looking at hematological remission and survival in adult relapsed / refractory B-precursor acute lymphoblastic leukemia patients.
Publications & conference data
6 peer-reviewed publications reference this trial (live from Europe PMC):
-
Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemia.
Gökbuget N, Kelsh M, Chia V, Advani A, et al · · 2016 · cited 95× · PMID 27662202 · DOI 10.1038/bcj.2016.84 -
Benefit-Risk Assessment of Blinatumomab in the Treatment of Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia.
Stein A, Franklin JL, Chia VM, Arrindell D, et al · · 2019 · cited 43× · PMID 30565020 · DOI 10.1007/s40264-018-0760-1 -
Role of allogeneic haematopoietic stem cell transplantation in the treatment of adult acute lymphoblastic leukaemia in the era of immunotherapy.
Sun W, Huang X. · · 2022 · cited 14× · PMID 34890382 · DOI 10.1097/cm9.0000000000001898 -
Estimating Long-Term Survival of Adults with Philadelphia Chromosome-Negative Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia Treated with Blinatumomab Using Historical Data.
Barlev A, Lin VW, Katz A, Hu K, et al · · 2017 · cited 12× · PMID 27873237 · DOI 10.1007/s12325-016-0447-x -
Immunotargeting relapsed or refractory precursor B-cell acute lymphoblastic leukemia - role of blinatumomab.
Queudeville M, Handgretinger R, Ebinger M. · · 2017 · cited 9× · PMID 28790849 · DOI 10.2147/ott.s103470 -
Blinatumomab bridges the gap between leukemia and immunity.
Yamazaki T, Galluzzi L. · · 2017 · cited 4× · PMID 29147620 · DOI 10.1080/2162402x.2017.1358335
Verify or expand the search:
- PubMed search for NCT02003612
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Acute Lymphoblastic Leukemia
Currently open trials in the same condition.
- NCT07020533 — A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Pa · Phase 1 · recruiting
- NCT07566377 — Cord Blood Transplantation in Children and Young Adults With Blood Cancer · Phase 2 · recruiting
- NCT05621291 — A Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-cell Recovery to Guide Management Follo · NA · recruiting
- NCT07356154 — A Study of Revumenib and Mezigdomide in People With Leukemia · Phase 1, PHASE2 · recruiting
- NCT07479927 — Telematic Cognitive Training and Mindfulness in Pediatric Patients After CAR-T Cell Therapy, Single Hematopoietic Alloge · NA · recruiting
Other Amgen trials
Trials by the same sponsor.
- NCT07223190 — A Study Evaluating Subcutaneous Versus Intravenous Blinatumomab in Newly Diagnosed Adults With B-cell Precursor Acute Ly · Phase 3 · not yet recruiting
- NCT07493512 — Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer · Phase 1 · not yet recruiting
- NCT07531095 — Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC) · Phase 1 · not yet recruiting
- NCT06987539 — A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Gen · Phase 2 · recruiting
- NCT05909761 — Observational Safety Study in Women With Neuromyelitis Optica Spectrum Disorder (NMOSD) Exposed to UPLIZNA® During Pregn · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02003612 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Amgen
- Last refreshed: 7 November 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02003612.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing